Category: Stock Market

The Mader Group Ltd (ASX: MAD) share price is in focus today after the company reported record FY26 revenue of $1.0 billion and net profit after tax (NPAT) of $65.4 million, both up 15% from last year.

What did Mader Group report?

• Revenue of $1,001.1 million, up 15% on the prior corresponding period (PCP)
• NPAT of $65.4 million, a 15% increase versus last year
• EBITDA of $120.7 million, rising 10% year on year
• Net cash position of $35.7 million, compared to net debt of $8.3 million in FY25
• No final dividend declared for FY26

What else do investors need to know?

Mader Group’s Australian business continued to grow, with services expanding across infrastructure and road transport. High-growth verticals and a strong market presence helped drive a 16% revenue increase in Australia.

In North America, revenue rose 12% (or ~17% in constant currency), supported by record headcount and expanding operations, especially in Canada. The Rest of World segment remains strategically important, with new business pursued in regions like New Zealand and Asia.

The company reported a Total Recordable Injury Frequency Rate of 3.65 per million hours and invested further in safety initiatives and community engagement, including support for events like the Mader Port to Pub and partnerships with Ronald McDonald House Charities and local Indigenous businesses.

What did Mader Group management say?

Executive Director & Chief Executive Officer Justin Nuich said:

I’m proud to announce that we have surpassed $1 billion in annual revenue, marking the successful delivery of the five-year strategic plan established by the Board in 2021… Achieving this milestone is a reflection of our people, our customers and a business model that continues to perform at scale… Looking ahead, with a strong culture, diversified service offering, and a scalable global platform, we are well-positioned to build on this momentum, capture the opportunities in front of us and continue to deliver long-term value for our shareholders.

What’s next for Mader Group?

The outlook for FY27 is upbeat, with Mader targeting at least $1.13 billion in revenue and NPAT of $72.5 million—growth of 13% and 11%, respectively. The company is investing in new service lines, growth initiatives, and an expanded long-term incentive program to underpin its ambition for approximately 15% compound annual growth over the next five years.

While no FY26 dividend was declared, the board continues to review capital allocation, and management remains focused on expanding Mader’s capabilities, strengthening its position in key markets, and supporting sustainable long-term growth.

Mader Group share price snapshot

Over the past 12 months, Mader Group shares have declined 13%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post Mader Group FY26 earnings: Profit jumps 15% on record revenue appeared first on The Motley Fool Australia.

More reading

• Tyro Payments FY26: Earnings rise, growth outlook improves
• ARB Corporation shares: FY26 profit drops but growth investments strengthen outlook
• Southern Cross Gold reports drilling results
• Viva Energy Group posts record 1H26 earnings, boosts dividend
• Scentre Group shares on watch as 2026 half year earnings climb and guidance gets a boost

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Mader Group. The Motley Fool Australia has positions in and has recommended Mader Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Scentre Group (ASX: SCG) share price is in focus today after the company reported funds from operations (FFO) of $612 million for the first half of 2026, up 4.4%, and upgraded its full year guidance for both earnings and distributions.

What did Scentre Group report?

• FFO for the half year: $612 million, up 4.4% (11.73 cents per security)
• Distribution for the half: $481 million, up 4.9% (9.215 cents per security)
• Statutory profit: $975 million, boosted by an unrealised property valuation increase of $478 million
• Annual customer visitations reached 552 million, a record for the business
• Occupancy remained high at 99.8%, the best in over a decade
• Upgraded 2026 full year guidance to at least 23.79 cents FFO and a distribution of 18.473 cents per security

What else do investors need to know?

Scentre Group delivered solid customer engagement and strong operational metrics. Customer advocacy improved, with its Net Promoter Score rising 12 points to 65, and Westfield membership grew to 5.2 million, up 11% on the previous year.

The group completed 1,401 leasing deals, with average specialty rent escalations of 5.5%. Business partners’ sales for the year reached a record $30.3 billion, growing 4.2% year on year. Scentre remains highly engaged in ongoing redevelopments at key destinations, including Westfield Bondi, Penrith, and Tuggerah.

On the capital management front, Scentre successfully introduced Australian Retirement Trust as a joint venture partner at Westfield Mt Gravatt and reduced its average debt margin from 2.6% to 1.6%. There is ample liquidity, with $3.5 billion available and all pandemic-era debt refinanced.

What did Scentre Group management say?

Scentre Group CEO Elliott Rusanow said:

Our focus is to continue generating long term earnings growth from our Westfield business in Australia and New Zealand and create significant additional value from our substantial land holdings.

What’s next for Scentre Group?

Management has upgraded full year 2026 FFO and distribution guidance, pointing to growth of at least 4.25%. Scentre is continuing to invest in its retail destinations and progress major redevelopments, especially at Westfield Bondi and other key sites.

At the same time, the group is looking to unlock value from its strategic land holdings by progressing plans to deliver up to 25,600 dwellings, working collaboratively with governments on housing supply. Scentre also aims to strengthen partnerships and drive further economic activity in and around its Westfield centres.

Scentre Group share price snapshot

The Scentre Group share price has underperformed the S&P/ASX 200 index (ASX: XJO) on a 12-month basis with a decline of around 8%.

View Original Announcement

The post Scentre Group shares on watch as 2026 half year earnings climb and guidance gets a boost appeared first on The Motley Fool Australia.

More reading

• Scentre Group sells 50% stake in Westfield Mt Gravatt to ART

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in Medical Developments International Ltd (ASX: MVP) are down slightly more than 20% over the past 12 months, but according to the analysts at Bell Potter there could be some serious upside from here.

Bell Potter has a buy recommendation on the shares and a bullish share price target which I’ll get to shortly. First let’s look at the company’s recently-released full year results.

Modest uplift in earnings

MVP last week announced a net profit of $600,000 for FY26, up from $100,000 for the previous year.

The company’s revenue was up 9% to $42.6 million.

The company’s main business involves the manufacture and sale of Penthrox, better know as the “green whistle” pain relief device.

MVP said in FY26 there was 28% volume growth of Penthrox in the Australian hospital segment and 18% growth in the European market.

Chief Executive Officer Brent McGregor said of the results:

We have delivered a solid financial performance in FY26 with strong cashflow generation. In our Pain Management segment we saw pleasing underlying growth, with stronger volumes in all regions. While demand in our Respiratory business was soft, pricing initiatives and lower costs helped deliver a modest improvement in segment earnings. Accelerating Penthrox volume growth was our priority in FY26. We are delighted by the progress we have made in the period on several important initiatives. This included obtaining regulatory approval for the paediatric indication of Penthrox in the UK and Europe. Penthrox can now be used by children 6 years of age and older in these markets – an important milestone for the Company. We expect to see benefits from access to the broader addressable market in future periods.

For FY27 MVP said it expected higher demand for Penthrox in Europe, “supported by the paediatric indication in Europe and the recently published health economic data”.

The company said the impact to earnings of Middle East supply chain disruptions and US tariffs remained uncertain and continued to be monitored.

Shares looking cheap broker says

Bell Potter said in a note to its clients that the result was broadly in line with their expectations, but they added that the company was poised for growth.

They said:

The completion of the transition in the European distribution arrangements for Penthrox lays a foundation for MVP to focus on improving demand and utilising the recent health economic analysis, published in “Emergency Medicine Australasia” to accelerate hospital adoption across geographical markets. MVP will be seeking to selectively open new markets, leveraging existing approvals and work towards improving the economic value of Penthrox.

Bell Potter has a price target of $1 on MVP shares compared to 50 cents currenty.

MVP is valued at $56.3 million.

The post This ASX small cap healthcare stock is tipped to double in value appeared first on The Motley Fool Australia.

More reading

• Tyro Payments FY26: Earnings rise, growth outlook improves
• ARB Corporation shares: FY26 profit drops but growth investments strengthen outlook
• Southern Cross Gold reports drilling results
• Viva Energy Group posts record 1H26 earnings, boosts dividend
• Mader Group FY26 earnings: Profit jumps 15% on record revenue

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Investors looking for a simple way to diversify their portfolios have plenty of Vanguard ETFs to choose from. But the popular Vanguard MSCI Index International Shares ETF (ASX: VGS) and Vanguard Australian Shares High Yield ETF (ASX: VHY) take very different approaches.

VGS offers global exposure and a tilt towards growth, while VHY focuses on high-yielding Australian shares.

So, which Vanguard ETF comes out on top?

VGS: Global growth in one ETF

This popular Vanguard ETF invests in around 1,300 companies across developed markets worldwide.

The US accounts for the bulk of the portfolio, with exposure to countries including Japan, the UK, Canada, France, Switzerland and Germany.

Its largest holdings include NVIDIA, Apple, and Microsoft. That gives investors exposure to some of the world’s biggest technology companies, alongside businesses across healthcare, consumer and industrial sectors. 

VGS charges a management fee of 0.18% per year. Over the past 12 months, it has delivered a return of around 7.4%. Over the past 10 years, the Vanguard ETF has returned approximately 184%.

VGS also recently paid a distribution of around 80 cents per unit.

VHY: The dividend-focused alternative

This popular Vanguard ETF takes a completely different approach.

Rather than looking overseas, VHY targets Australian companies with higher forecast dividend yields. Its major holdings include BHP Group Ltd (ASX: BHP), Westpac Banking Corp (ASX: WBC), Rio Tinto Ltd (ASX: RIO) and Telstra Group Ltd (ASX: TLS), alongside other major Australian companies. 

For income-focused investors, that’s the major attraction. The fund carries a forecast yield of around 4.2%, rising to approximately 5.5% once franking credits are included.

And VHY hasn’t exactly been left behind on performance. It delivered a 7.4% return over the past year and a return of 46% over the past decade. 

VHY charges a 0.25% management fee, slightly more than VGS. Its portfolio also has significant exposure to the Australian banking and resources sectors, meaning investors aren’t getting the same geographic or sector diversification offered by VGS.

Which Vanguard ETF wins?

There isn’t an obvious winner for every investor. VHY could be the better fit for investors who prioritise regular dividend income and want exposure to established Australian businesses. The potential benefit of franking credits is another attraction for eligible Australian investors.

VGS, meanwhile, offers something VHY simply can’t: global diversification and access to sectors such as technology that have a much smaller presence on the Australian share market. 

For an investor focused primarily on long-term capital growth and diversification, I’d give VGS the edge.

But for investors seeking income today, VHY has a compelling proposition.

Ultimately, the better Vanguard ETF depends on whether your priority is global growth or Australian dividend income.

The post VGS vs VHY: Which Vanguard ETF comes out on top? appeared first on The Motley Fool Australia.

More reading

• Why every Aussie investor should own one of these ASX ETFs
• With profits surging to $13.7 billion, are BHP shares a buy, hold or sell now?
• How much superannuation do I need to earn $4,000 a month in passive income?
• BHP shares just hit a record high. Can the run continue?
• Are Westpac shares a buy at their new 52-week low?

Motley Fool contributor Marc Van Dinther has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Apple, Microsoft, and Nvidia. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended Apple, BHP Group, Microsoft, Nvidia, Vanguard Australian Shares High Yield ETF, and Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Westgold Resources Ltd (ASX: WGX) share price is in focus today after the company unveiled a major expansion plan for its Meekatharra processing hub, aiming to significantly boost gold production and improve future cashflow.

What did Westgold Resources report?

• Scoping Study for Meekatharra Expansion Plan (MXP) to lift processing capacity from 1.8Mtpa to 2.9Mtpa in FY28
• Expected to add approximately 47,000 ounces per year to gold production, increasing total gold output to 1.6 million ounces over 10 years (up 424,000 ounces)
• Indicative capital cost of $100 million with a targeted payback period of 9 months
• All-in Sustaining Cost (AISC) range forecast between $1,968 – $2,406 per ounce for life-of-mine
• Group NPV uplift of about $1.1 billion at $5,500/oz gold price, up to $1.6 billion at spot ($6,000/oz)
• Westgold holds $939 million in cash, bullion and liquid investments as at 30 June 2026

What else do investors need to know?

The Meekatharra Expansion Plan is designed as a low-capital, brownfields upgrade, leveraging existing infrastructure and equipment that’s already on hand. By installing a parallel crushing and single-stage SAG milling circuit, Westgold aims to process more ore and unlock additional emerging supply, including increased outputs from the Bluebird–South Junction mine and several open pits in its Murchison Open Pit program.

Resource definition drilling and open pit optimisation work has already commenced to further support and de-risk the expansion. Third-party ore purchase agreements are also in place, providing additional flexibility, although these are not critical to the project’s economics.

What did Westgold Resources management say?

Westgold Managing Director and CEO Wayne Bramwell said:

The MXP is a capital-efficient brownfields expansion option to address this emerging constraint. It utilises existing infrastructure and long-lead equipment already procured to increase processing capacity from 1.8Mtpa to 2.9Mtpa, without the capital intensity, execution risk or timeframe of building a new plant.

What’s next for Westgold Resources?

Westgold will now move forward with feasibility-level studies, detailed engineering and execution planning for the Meekatharra expansion, aiming for a final investment decision in late FY27. Brownfields resource definition work will continue in parallel to secure additional future ore sources.

If delivered as planned, the MXP is expected to lift installed capacity in FY28, setting up improved production, lower processing costs and enhanced free cash generation for the group. Production timing and costs remain subject to feasibility outcomes and final approvals.

Westgold Resources share price snapshot

Over the past 12 months, Westgold Resources shares have risen 97%, significantly outperforming the S&P/ASX 200 Index (ASX: XJO).

View Original Announcement

The post Westgold Resources launches $100m Meekatharra expansion plan to boost output appeared first on The Motley Fool Australia.

More reading

• Westgold Resources lifts Ore Reserves by 41% in 2026 update
• 5 things to watch on the ASX 200 on Wednesday
• Westgold Resources: Maiden Fletcher Ore Reserve announcement
• 5 things to watch on the ASX 200 on Wednesday
• 3 ASX 200 stocks storming higher this week on big news

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

It has been a rollercoaster ride for PLS Group Ltd (ASX: PLS) shareholders in 2026. 

The lithium-tantalum producer saw its share price open the year around $4.30 per share. 

After a strong run for lithium shares amidst renewed sector optimism, its share price hit over $6.70 per share. 

Investors’ happiness was short lived however, as it quickly plummeted back down to $4.00 per share in a matter of weeks. 

Since then, it has slowly climbed back into the positive, before PLS shares roared back to life yesterday following full year results. 

This volatility can make it difficult for investors to pinpoint true value. 

However the team at Bell Potter have provided updated guidance for what investors can expect over the next 12 months. 

What did PLS report?

As reported by The Motley Fool yesterday, the company reported FY26 revenue up 152% to $1.93 billion and a shift to a $526 million net profit.

Other results included: 

• Underlying EBITDA: $1,137 million (59% margin; up from $97 million in FY25)
• Net profit after tax: $526 million (from a $196 million loss in FY25)
• Production: 879.5k tonnes spodumene concentrate (up 17%)
• Final dividend: 5 cents per share, fully franked ($161 million distribution)
• Cash balance: $2,290 million (up 135%). 

Investors were seemingly pleased with these results as PLS shares rose by almost 8% yesterday. 

Its share price is now up more than 150% in the last 12 months. 

What is Bell Potter’s view?

The broker saw the FY26 result as broadly in line with expectations, with strong cash generation and a better-than-expected 5c fully franked dividend. 

However, PLS is now entering a large investment cycle, with FY27 capex expected to rise significantly as it progresses projects.

Bell Potter expects the P2000 project could receive investment approval in late 2026, but estimates its cost at around $2.2bn, well above the earlier $1.2bn estimate. 

While PLS has a strong balance sheet with $1.1bn net cash, Bell Potter believes the increased spending and PLS’s conservative approach to its balance sheet could limit shareholder returns in the medium term, despite only modest changes to its earnings forecasts.

Hold recommendation for PLS shares

Based on this guidance, the broker has a hold recommendation on PLS shares. 

The broker also has a price target of $5.20 on PLS shares, indicating a 5% downside from current levels. 

With the material step up in expenditure and the company’s track record for balance sheet conservatism, we believe shareholder returns could be constrained across the medium term.

The post What is this broker’s updated view on PLS shares after big results? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• 2 ASX shares that could rise up to 45% following earnings results 
• The fantastic dividend stock with upside investors should be targeting this week
• Here are the top 10 ASX 200 shares today
• Everything you need to know about the PLS Group dividend

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Coles Group Ltd (ASX: COL) share price will be closely watched today after full-year sales revenue rose 2.8% to $45.6 billion and earnings (EBIT, excluding significant items) jumped 9.9%, led by strong Supermarkets performance.

What did Coles Group report?

• Group sales revenue up 2.8% to $45,580 million
• EBIT (excluding significant items) up 9.9% to $2,322 million
• NPAT (excluding significant items) up 13.7% to $1,255 million
• Fully franked total dividend up 13.0% to 78 cents per share
• Supermarkets sales revenue up 3.7%, EBIT up 12.2%
• eCommerce Supermarkets sales grew 26.4% to $5.6 billion

What else do investors need to know?

Coles delivered strong returns from its core Supermarkets business, with EBIT margin expanding by 43 basis points and customer satisfaction scores improving. Notably, Exclusive to Coles sales grew 6.1%, and the company gained market share during the year.

Liquor sales revenue fell 3.3% as the sector faced subdued consumer sentiment and higher costs, prompting the launch of a multi-year repositioning program. The group maintained a robust balance sheet with net assets of $3.95 billion and continued to invest in store renewals, automation, and digital technology.

Coles declared a fully franked final dividend of 37 cents per share, taking dividends for the year to 78 cents — a 13% increase.

What did Coles Group management say?

Commenting on the results, Coles CEO, Leah Weckert, said:

FY26 was another year of consistently strong performance for Coles, with above-market sales and strong earnings growth accompanied by further improvements in customer NPS and team member engagement. This demonstrates the benefits of our investments in automation and eCommerce, disciplined execution and a focus on delivering clear value for customers. We are now investing in the next phase of growth, including through an accelerated store opening and renewal program, coupled with a clear strategy to improve the performance of our Liquor business which will ensure Coles can maintain its growth trajectory.

What’s next for Coles Group?

Coles enters FY27 with positive momentum, especially across Supermarkets and digital operations, with sales growth tracking similarly to the final quarter of FY26. The business is ramping up investment in new stores, renewals, and technology—including accelerated eCommerce and supply chain automation.

For Liquor, a strategic repositioning is underway to improve integration with Supermarkets, optimise the store network, and simplify operations. The company will also invest in its new Victorian automated distribution centre and the Coles Capability Centre to drive operational efficiencies and support long-term growth.

Coles Group share price snapshot

Over the past 12 months, the Coles Group share price has outperformed the S&P/ASX 200 index (ASX: XJO) with a gain of around 9%. This reflects ongoing investor confidence in the business’s steady performance and dividend growth.

View Original Announcement

The post Coles Group grows profit and dividend as Supermarkets shine in FY26 appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• 7 ASX 200 shares with reaffirmed buy ratings this week
• Is the Coles share price good value?
• 3 ASX shares I’d buy if I could only check my portfolio once a year
• Reporting season half-time report: 5 lessons from August so far

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The South32 Ltd (ASX: S32) share price is in focus today after the company reported a substantial 61% jump in Sierra Gorda’s ore reserve estimate, extending the mine’s reserve life to 2045.

What did South32 report?

• Ore reserve at Sierra Gorda increased by 61% to 1,100 million tonnes at 0.39% total copper, 0.016% molybdenum, and 0.06 g/t gold (as at 31 July 2026).
• Mineral resource estimate rose 8% to 1,870 million tonnes at 0.37% total copper, 0.016% molybdenum, and 0.06 g/t gold.
• Reserve life extended by about five years, now expected until 2045.
• Expansion follows successful infill drilling—around 85,000 metres drilled between 2023 and 2025.
• Fourth grinding line project approved, projected to boost copper production by around 30% from 2031.

What else do investors need to know?

The Sierra Gorda copper mine, in which South32 holds a 45% stake, is a large, open pit operation in northern Chile. This major jump in ore reserves and resources comes after significant drilling to better define the orebody, providing more certainty over future production.

July’s approval for a fourth grinding line is expected to increase annual processing capacity from 135,000 to 165,000 tonnes per day by 2031. The mine is already well-equipped with modern processing infrastructure, renewable energy, and seawater supply, helping support these plans.

Exploration is underway at the Catabela Northeast zone, where early drilling results suggest more copper resources could be uncovered—potentially providing further mine life extensions in the future.

What did South32 management say?

South32 Chief Executive Officer, Matt Daley said:

This update highlights the scale, quality and long-life orebody at Sierra Gorda, which we expect will be a significant source of copper for decades to come. It follows the approval in July to proceed with execution of the fourth grinding line project at Sierra Gorda, which is expected to increase copper production by approximately 30 per cent from 2031.

With the current orebody remaining open at depth, the mine offers potential for further growth beyond today’s increase to ore reserve and reserve life. We continue to work with our joint venture partner to drive further growth and value at Sierra Gorda. This includes the Catabela Northeast exploration project, where exploration holes have intersected significant copper mineralisation, highlighting the potential for future mine life extension.

What’s next for South32?

South32 is focused on ramping up development at Sierra Gorda, progressing the fourth grinding line project and ongoing infill and exploration drilling. With the orebody remaining open at depth and encouraging early drilling outside current reserves, investors can expect continued efforts to grow resources and sustain the mine’s future.

The company is also progressing environmental permit approvals to cover operations beyond 2035, aiming for a seamless transition to an extended mine life. Management highlights Sierra Gorda’s role as a cornerstone copper asset as global demand for key energy transition minerals rises.

South32 share price snapshot

The South32 share price has smashed the S&P/ASX 200 index (ASX: S32) over the past 12 months with a gain of over 70%.

View Original Announcement

The post South32 share price in focus as Sierra Gorda mine life jumps with 61% reserve boost appeared first on The Motley Fool Australia.

More reading

• Bell Potter names the best ASX shares to buy in August
• South32 shares hit 10-year high: What’s next?
• 8 ASX 200 shares with renewed buy ratings this week
• South32 shares leap 26% to fresh 4-year high: Here’s what brokers expect next
• 2 ASX shares highly recommended to buy: Experts

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Aurelia Metals Ltd (ASX: AMI) share price is in focus today after the company announced the appointment of Mr Steve Badenhorst as its new Managing Director and Chief Executive Officer, set to begin on 6 October 2026.

What did Aurelia Metals report?

• Appointment of Steve Badenhorst as Managing Director and Chief Executive Officer
• Badenhorst brings 35+ years of global mining and operational leadership experience
• Recent leadership roles include Group Head of Asset Management at Rio Tinto and COO at Rio Tinto Aluminium Pacific Operations
• TFR (Total Fixed Remuneration) of $732,500 per annum, plus short- and long-term incentives
• Badenhorst commences on 6 October 2026

What else do investors need to know?

Aurelia Metals operates three underground base metal mines across its Peak and Federation sites in the Cobar Basin, NSW, and is developing its Great Cobar copper project. The appointment follows a comprehensive recruitment process to secure a leader with strong operational credentials and long-term strategic vision.

Outgoing interim CEO Martin Cummings will step down when Badenhorst begins his role. Aurelia’s board expressed gratitude for Cummings’ leadership during the transition period.

What did Aurelia Metals management say?

Commenting on his appointment, Steve Badenhorst said:

I am honoured to be appointed Managing Director and Chief Executive Officer of Aurelia, to lead the Company through its next phase of growth. Aurelia has a high quality asset base, a strong team and significant opportunities to create value through safe, predictable operational performance, resource development and continued exploration success.

I am excited to return to underground hard rock mining and look forward to working closely with the Board and the Executive Leadership Team to execute the Company’s strategy to realise the potential of the Company’s operations and highly prospective exploration portfolio to create long-term value for shareholders.

What’s next for Aurelia Metals?

With Mr Badenhorst set to start in early October, Aurelia Metals will soon be under experienced new leadership expected to drive its growth strategy forward. The company aims to deliver on its plans for resource development and to progress major projects like Great Cobar, focusing on creating sustainable long-term value for shareholders.

Investors can watch for updates on strategic initiatives, operational improvements, and exploration results as the new CEO settles in.

Aurelia Metals share price snapshot

Over the past 12 months, Aurelia Metals shares have risen 116%, significantly outperforming the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post Aurelia Metals appoints Steve Badenhorst as new CEO to lead next growth phase appeared first on The Motley Fool Australia.

More reading

• Tyro Payments FY26: Earnings rise, growth outlook improves
• ARB Corporation shares: FY26 profit drops but growth investments strengthen outlook
• Southern Cross Gold reports drilling results
• Viva Energy Group posts record 1H26 earnings, boosts dividend
• Mader Group FY26 earnings: Profit jumps 15% on record revenue

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus after its global partner, Acadia Pharmaceuticals, secured European approval for DAYBU (trofinetide) – the first treatment for Rett syndrome in the EU. Neuren stands to receive US$35 million upon the drug’s first commercial sale in Europe, plus potential milestone payments.

What did Neuren report?

• The European Commission has granted marketing authorisation for DAYBU (trofinetide) for Rett syndrome.
• DAYBU is the first and only approved treatment for Rett syndrome in the European Union.
• Neuren to receive US$35 million from the first European commercial sale, with milestone payments up to US$170 million.
• Tiered royalties from mid-teens to low 20s percent of net sales are also expected under the partnership.
• Commercial launch in Germany is targeted for early Q4 2026.

What else do investors need to know?

The European approval means DAYBU can be marketed across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. This milestone further extends the reach of trofinetide, which is already approved in the United States, Canada, and Israel.

Neuren’s other clinical program, NNZ-2591, is progressing with a Phase 3 clinical trial for Phelan-McDermid syndrome and open-label extension studies. Each of Neuren’s drug development programs has been granted “orphan drug” status in both the US and EU.

What did Neuren management say?

Neuren CEO Jon Pilcher said:

We are delighted for the Rett syndrome community in Europe, who, until now, have had no approved treatment for this devastating condition. The European Commission’s approval of DAYBU is particularly rewarding for Neuren given our long-standing commitment to developing therapies for serious neurological disorders with profound unmet need. We look forward to seeing our partner Acadia make DAYBU available for Rett patients and families in Europe.

What’s next for Neuren?

With European marketing authorisation, Acadia plans to launch DAYBU in Germany in early Q4 2026, which will trigger Neuren’s first commercial milestone payment. Ongoing development of NNZ-2591, now in late-stage trials for several neurodevelopmental disorders, remains a key priority for future growth.

Neuren continues to target serious neurological conditions where few approved treatments exist, aiming to advance both its existing partnerships and its internal drug pipeline.

Neuren share price snapshot

The Neuren Pharmaceuticals share price has outperformed the S&P/ASX 200 index (ASX: XJO) over the past 12 months with a gain of approximately 27%.

View Original Announcement

The post Neuren share price in focus after DAYBU wins EU approval for Rett syndrome appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 3 ASX 200 stocks storming higher this week on big news
• 5 ASX 200 broker buy ratings
• Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.